Now I have a complete understanding of the paper. Let me compose the final consolidated review.

## Summary

This paper proposes MUSE, a graph contrastive learning framework for multimodal patient representation learning that simultaneously addresses both missing modalities and missing labels — a realistic but under-studied clinical scenario. MUSE constructs a bipartite patient-modality graph and uses a mutual-consistent contrastive loss (unsupervised edge-dropout contrast + supervised label-based contrast) to learn modality-agnostic and label-decisive features. The unsupervised component further allows training on patients without labels (MUSE+). Experiments on MIMIC-IV, eICU, and ADNI show consistent improvements over existing methods, with MUSE achieving ~2% absolute AUC-ROC improvement over graph-based baselines and MUSE+ reaching ~4%.

## Strengths

1. **Realistic and well-motivated problem formulation.** The paper explicitly targets the joint challenge of missing modalities AND missing labels, which prior multimodal learning works either ignore (assuming complete data) or only partially address (missing modalities but not labels). This is clearly motivated with clinical examples (line 20) and visualized in Figure 1. MUSE+'s ability to incorporate unlabeled patients via the unsupervised contrastive objective directly addresses this gap, and the ~3–4% absolute improvement on ICU datasets (Tables 1–2) demonstrates practical value.

2. **Clean and principled method design.** The bipartite patient-modality graph construction (Section 3.1) naturally handles arbitrary missing patterns through graph structure rather than complex imputation, and the mutual-consistent contrastive loss (Section 3.2) directly targets the modality collapse problem with a simple, interpretable objective. The edge-dropout augmentation is a lightweight way to simulate missing modalities during training, and the ablation study (Table 3) confirms each component contributes meaningfully.

3. **Empirical evidence for modality-agnostic representations.** The cosine similarity analysis (Figure 4) directly measures whether same-patient representations stay consistent under different missing modality patterns. MUSE achieves the highest similarity score, providing quantitative support for the central claim that the method learns representations robust to missing modalities. This is stronger than relying on downstream accuracy alone.

4. **Thorough experimental evaluation across diverse clinical settings.** The paper evaluates on three public datasets covering ICU (MIMIC-IV, eICU) and Alzheimer's disease (ADNI), with two prediction tasks each, multiple metrics (AUC-ROC, AUC-PR, balanced accuracy), bootstrapped confidence intervals, and statistical significance testing. The missing-rate analysis (Figure 3) and runtime comparison (Figure 5) further characterize the method's behavior.

## Weaknesses

### Fatal
None.

### Major
None.

### Minor

1. **ADNI results have high variance relative to the reported gains.** The paper itself acknowledges (line 172) that standard deviations on ADNI are larger (>0.02), yet the improvement of MUSE over the best baseline is modest (approximately 0.008–0.019 depending on the metric). While the paper reports significant improvements via t-tests (marked with asterisks), no multiple-testing correction is applied across the four metrics and three datasets, and with the reported standard deviations, some of these differences fall within one standard error. The paper would benefit from reporting effect sizes or confidence intervals for the differences, and from being more measured in its claims about ADNI results.

2. **The MUSE+ comparison lacks a semi-supervised baseline.** MUSE+ gains ~2% additional improvement by incorporating unlabeled patients, but no baseline method is extended to use unlabeled data in any way (e.g., self-supervised pre-training, pseudo-labeling, or graph-based semi-supervised learning). While this does not invalidate MUSE+ — the comparison to MUSE itself (which uses the same labeled patients as all baselines) is fair and shows gains — a semi-supervised variant of GRAPE or M3Care would strengthen the claim that MUSE+'s advantage comes from its specific contrastive design rather than merely from having more data.

3. **Key hyperparameters are not justified or reported.** The edge-dropout rate (0.15) is fixed without sensitivity analysis, and the temperature parameter τ in the contrastive loss (Eqs. 5–6) is not given a value in the main text. While these may appear in the appendix (stripped by the parser), the main text would benefit from stating τ's value and including a sensitivity study for the edge-dropout rate, which is central to the augmentation strategy.

4. **No limitations discussion.** The paper does not discuss any limitations of the approach, such as: the assumption that all modalities share a common embedding dimension, the requirement that each patient has at least one modality to be represented in the graph, or the scalability of the bipartite graph to very large patient cohorts (millions). Including a limitations section would strengthen the paper's scholarly rigor.

5. **Label-decisiveness claim is not directly evaluated.** The cosine similarity analysis (Figure 4) convincingly shows modality-agnostic representations, but the paper does not directly evaluate whether the representations are more "label-decisive" — e.g., whether same-label patients cluster better under MUSE than under baselines. A t-SNE visualization or a nearest-neighbor label-consistency analysis would strengthen this claim.

### Trivial
- The abstract's phrasing "MUSE+ further elevates the absolute improvement to ~4%" is ambiguous about the reference point (improvement over what? baselines? MUSE?). Clarify in revision.

## Nice-to-Haves
- An analysis of performance when entire modality groups are removed at test time would directly demonstrate robustness to missing modalities, complementing the cosine similarity analysis (which only varies random masks).
- A sensitivity analysis on the edge-dropout rate ({0.05, 0.1, 0.2, 0.3}) and the temperature τ would demonstrate robustness to hyperparameter choice.
- Reporting the number of labeled vs. unlabeled patients for each dataset would clarify the setting for MUSE+.
- A baseline extending GRAPE with self-supervised pre-training on unlabeled data would strengthen the MUSE+ comparison.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **Criticism that A2 is not a fair proxy for GRAPE and that the paper doesn't control for augmentation**: REMOVED — this misreads the ablation. A2 (removing all contrastive loss, keeping edge-dropout augmentation and CE loss) is exactly "GRAPE + edge-dropout augmentation without contrastive loss." Comparing A2 vs. MUSE isolates the effect of the contrastive objectives on top of augmentation. The paper already provides the requested control. Similarly, the critic's request for "GRAPE + supervised contrastive loss" is addressed by A4 (removes unsupervised contrastive loss, keeps supervised contrastive loss).

- **Criticism that baseline training times are not reported**: REMOVED — Figure 5 plots AUC-ROC vs. per-epoch training time for all methods, including baselines. Training times are reported.

- **Formatting/style nitpicks about grayscale readability of Figure 3, missing Figure 4 caption, and "garbled text"**: REMOVED — these are parser artifacts, not author errors.

- **Reproducibility concerns about undisclosed hyperparameters (number of layers, hidden dimension, batch size, learning rate, optimizer)**: REMOVED — the paper states "More implementation details are provided in Appx. C" (line 137), which was stripped by the parser. These details exist in the original submission.

- **Criticism that "MT" baseline is not explained**: REMOVED — the Related Work section (line 224) describes MT as "a late-fusion Transformer layer to model the interaction among modalities." The description is present.

## Novel Insights

Beyond the paper's own contributions, the reviews surface an interesting tension: the paper's cleanest and most convincing results (ICU datasets with ~2% improvement and clear cosine-similarity separation) come from the setting that is most similar to existing work (GRAPE on labeled data only), while the most impressive-sounding result (~4% from MUSE+) is also the hardest to definitively attribute to the method's design, given the absence of any semi-supervised baseline. This pattern — where the headline number rests on a comparison that is asymmetric in data usage — is common in the multi-modal and clinical ML literature and suggests the community would benefit from standardized protocols for evaluating methods that use unlabeled data, analogous to the protocol in this paper for labeled-only comparisons.

## Suggestions

1. **In a revision, add a semi-supervised baseline** — extend GRAPE with a self-supervised pre-training objective (e.g., modality reconstruction or edge prediction) on unlabeled data, then fine-tune on labeled data. This would directly test whether MUSE+'s advantage over "more data + simple pre-training" is real.

2. **Report N_labeled and N_unlabeled for each dataset** so readers can assess the data regime in which MUSE+ operates.

3. **Include a hyperparameter sensitivity analysis** for the edge-dropout rate (e.g., sweeping {0.05, 0.1, 0.2, 0.3}) and report the temperature τ value.

4. **Add a modality-removal experiment**: train on all modalities, then at test time remove entire modality groups (e.g., all notes, all labs) and measure the performance drop. If MUSE degrades less than GRAPE, this is direct evidence of modality-agnostic learning.

5. **Discuss limitations** explicitly, including scalability to very large patient cohorts, the requirement of at least one modality per patient, and the fixed embedding dimension assumption.

## Score and Decision

The paper addresses a realistic and important problem with a clean, well-motivated method. The experimental evaluation is generally thorough, covering three datasets, multiple tasks, ablation studies, representation analysis, and runtime comparisons. The minor weaknesses identified (ADNI variance, lack of semi-supervised baseline for MUSE+, missing hyperparameter sensitivity) do not invalidate the core contribution and are largely addressable. The paper makes a solid contribution to the field of multimodal patient representation learning.

MY FINAL SCORE: <pineapple>7.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>